|
|
News
- miRagen Therapeutics to Present at Biotech Showcase 2012
- January 5, 2012
- miRagen Therapeutics Publishes Data Demonstrating that Therapeutic Dosing of miR-15 Family Inhibitor Protects Against Ischemic Injury to the Heart
- November 3, 2011
- Servier and miRagen Sign $352 Million Partnership Agreement for the Research, Development and Commercialization of MicroRNA-targeting Drugs for Cardiovascular Disease
- October 18, 2011
- Therapeutic Dosing of Synthetic AntimiR Further Demonstrates the Potential of microRNA-208 Inhibition in Treatment of Chronic Heart Failure
- September 6, 2011
- RxGen and miRagen Announce Award of NIH-NHLBI SBIR Grant to Fund Advanced Preclinical Studies Evaluating the Role of microRNAs in Cardiac Disease
- August 25, 2011
- miRagen Therapeutics and Collaborators Identify Critical Role of microRNA-15 in Cardiomyogenesis
- July 26, 2011
- miRagen Therapeutics and Collaborators Identify Key Role for miR-133a as a Modulator of Skeletal Muscle Disorder
- July 1, 2011
- miRagen Receives Notice of Allowance for Intellectual Property for MicroRNAs that Modulate Smooth Muscle Proliferation and Differentiation
- June 21, 2011
- miRagen Therapeutics Receives Orphan Drug Designation for MGN-4893 for the Treatment of Polycythemia Vera
- February 17, 2011
- miRagen to Present New Data at First Keystone MicroRNAs and Human Disease Conference
- February 11, 2011
- miRagen Therapeutics Named University of Colorado Technology Transfer Office Bioscience Company of the Year
- January 18, 2011
- miRagen Therapeutics and t2cure Sign Licensing Agreement for microRNA Target Implicated in Vascular Disease
- November 30, 2010
- miRagen Therapeutics Signs Research and Licensing Agreements with University of Colorado for microRNA Profiling of Human Heart Failure Study
- October 26, 2010
- miRagen Therapeutics’ Director of Biology to Give Plenary Lecture at Center for Heart Failure Research Symposium in Oslo, Norway
- September 30, 2010
- miRagen Therapeutics Announces Identification of a microRNA as Key Regulator of Blood Cell Development
- July 31, 2010
- Santaris Pharma A/S and miRagen Therapeutics, Inc. Form Strategic Alliance
- June 23, 2010
- miRagen’s Director of Biology to Give Keynote Lecture
- May 25, 2010
- miRagen’s Chief Scientific Advisor to Give Plenary Lecture at Joint ASCI-AAP Meeting
- April 23, 2010
- miRagen and RXi Announce Research Collaboration
- April 12, 2010
- miRagen Establishes Premier Scientific Advisory Board
- January 11, 2010
- miRagen Announces Discovery of Key microRNA Implicated in Lou Gehrig’s Disease
- December 10, 2009
- miRagen Named 2009 Rising Star of the Year
- November 19, 2009
- Dr. Thomas E. Hughes Elected to miRagen Board
- October 15, 2009
- miRagen and Archemix Announce Collaboration
- July 23, 2009
- Chief Scientific Advisor Wins Prestigious Award for Heart Research
- June 9, 2009
- miRagen Accomplishes Funding Milestones and Secures Series A Extension
- June 2, 2009
- Chief Scientific Advisor Wins National Research Achievement Award
- November 13, 2008
- microRNA Perturbations Following Acute MI
- September 2, 2008
- Miragen Therapeutics, Inc. Receives $8 M in Venture Capital Financing for Development of MicroRNA-based Therapies
- May 19, 2008
|
